• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

N348I 突变对非 B 型 HIV-1 中 HIV-1 逆转录酶的非核苷类逆转录酶抑制剂耐药性的影响。

Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.

机构信息

Centre of Virology, Royal Free and University College London Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom.

出版信息

Antimicrob Agents Chemother. 2011 Apr;55(4):1806-9. doi: 10.1128/AAC.01197-10. Epub 2011 Jan 31.

DOI:10.1128/AAC.01197-10
PMID:21282419
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3067126/
Abstract

We investigated the effect of N348I alone and with M184V on nonnucleoside reverse transcriptase inhibitor (NNRTI) drug susceptibility and replicative capacity in B and non-B HIV-1 isolates. N348I reduced the susceptibility to all NNRTI drugs across subtypes. The replication capacity of all viruses in a variety of cell lines was impaired by N348I. Interestingly, the N348I and M184V double mutation compensated for the reduced NNRTI drug susceptibility observed in the N348I single mutant and marginally improved viral replicative capacity.

摘要

我们研究了 N348I 单独存在和与 M184V 共同存在对 B 型和非 B 型 HIV-1 分离物中非核苷类逆转录酶抑制剂（NNRTI）药物敏感性和复制能力的影响。N348I 降低了所有 NNRTI 药物对所有亚型的敏感性。N348I 还削弱了所有病毒在多种细胞系中的复制能力。有趣的是，N348I 和 M184V 双重突变补偿了 N348I 单突变体中观察到的 NNRTI 药物敏感性降低，并略微提高了病毒复制能力。

相似文献

1
Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.N348I 突变对非 B 型 HIV-1 中 HIV-1 逆转录酶的非核苷类逆转录酶抑制剂耐药性的影响。
Antimicrob Agents Chemother. 2011 Apr;55(4):1806-9. doi: 10.1128/AAC.01197-10. Epub 2011 Jan 31.
2
Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.K101E 取代在 HIV-1 逆转录酶中对利匹韦林和其他非核苷类逆转录酶抑制剂耐药中的作用。
Antimicrob Agents Chemother. 2013 Nov;57(11):5649-57. doi: 10.1128/AAC.01536-13. Epub 2013 Sep 3.
3
The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.HIV-1 逆转录酶中的连接域突变 N348I 增强了对依曲韦林和利匹韦林的耐药性，但通过降低病毒复制能力限制了 E138K 耐药突变的出现。
J Virol. 2014 Feb;88(3):1536-47. doi: 10.1128/JVI.02904-13. Epub 2013 Nov 13.
4
Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.1型人类免疫缺陷病毒逆转录酶连接亚结构域中的氨基酸突变N348I赋予对核苷类和非核苷类逆转录酶抑制剂的多类耐药性。
J Virol. 2008 Apr;82(7):3261-70. doi: 10.1128/JVI.01154-07. Epub 2008 Jan 23.
5
Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.非核苷类逆转录酶抑制剂体外耐药选择过程中非 B 型 HIV-1 的不同突变途径。
Antimicrob Agents Chemother. 2010 Nov;54(11):4812-24. doi: 10.1128/AAC.00829-10. Epub 2010 Aug 30.
6
Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.HIV逆转录酶中W153L替换对病毒复制及对多类逆转录酶抑制剂耐药性的影响。
Antimicrob Agents Chemother. 2014 Aug;58(8):4515-26. doi: 10.1128/AAC.02729-14. Epub 2014 May 27.
7
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.耐奈韦拉平、依非韦伦、埃替拉韦和利匹韦林的原型重组传染性分子克隆耐药性面板。
Antimicrob Agents Chemother. 2012 Aug;56(8):4522-4. doi: 10.1128/AAC.00648-12. Epub 2012 Jun 4.
8
Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.人类免疫缺陷病毒 1 型逆转录酶连接域突变的组合：评估对核苷和非核苷逆转录酶抑制剂耐药性的影响。
Antimicrob Agents Chemother. 2010 May;54(5):1973-80. doi: 10.1128/AAC.00870-09. Epub 2010 Mar 1.
9
Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.携带可导致非核苷类逆转录酶和整合酶链转移抑制剂耐药突变的 HIV-1 中病毒适应性和药物敏感性的改变。
J Virol. 2014 Aug;88(16):9268-76. doi: 10.1128/JVI.00695-14. Epub 2014 Jun 4.
10
Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.人类免疫缺陷病毒 1 型逆转录酶中的 V106I 和 V179D 多态性突变的组合赋予了对依非韦伦和奈韦拉平的耐药性，但对埃替拉韦则没有。
Antimicrob Agents Chemother. 2010 Apr;54(4):1596-602. doi: 10.1128/AAC.01480-09. Epub 2010 Feb 1.

引用本文的文献

1
Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan.哈萨克斯坦 HIV 感染者中的抗逆转录病毒治疗耐药突变。
Sci Rep. 2022 Oct 13;12(1):17195. doi: 10.1038/s41598-022-22163-7.
2
HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.尽管存在表型耐药性，一线方案仍能实现 HIV-1 再抑制。
PLoS One. 2020 Jun 18;15(6):e0234937. doi: 10.1371/journal.pone.0234937. eCollection 2020.
3
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.在低收入和中等收入国家，开始或重新开始一线抗逆转录病毒治疗之前的 HIV-1 耐药性：系统评价和荟萃回归分析。
Lancet Infect Dis. 2018 Mar;18(3):346-355. doi: 10.1016/S1473-3099(17)30702-8. Epub 2017 Dec 5.
4
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.在撒哈拉以南非洲地区，基于齐多夫定的一线抗逆转录病毒治疗出现长期病毒学失败后，HIV-1胸苷类似物突变的快速积累及其表型影响
J Antimicrob Chemother. 2017 May 1;72(5):1450-1455. doi: 10.1093/jac/dkw583.
5
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.撒哈拉以南非洲地区一线替诺福韦联合胞嘧啶类似物及奈韦拉平或依非韦伦治疗失败后，人类免疫缺陷病毒1型（HIV-1）对胸腺嘧啶类似物的隐匿性耐药：一项回顾性多中心队列研究
Lancet Infect Dis. 2017 Mar;17(3):296-304. doi: 10.1016/S1473-3099(16)30469-8. Epub 2016 Dec 1.
6
Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.非B亚型HIV-1的耐药性：HIV-1逆转录酶抑制剂的影响
Viruses. 2014 Sep 24;6(9):3535-62. doi: 10.3390/v6093535.
7
Compensatory role of double mutation N348I/M184V on nevirapine binding landscape: insight from molecular dynamics simulation.双重突变N348I/M184V对奈韦拉平结合态势的补偿作用：来自分子动力学模拟的见解
Protein J. 2014 Oct;33(5):432-46. doi: 10.1007/s10930-014-9576-8.
8
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.在乌干达出现长期病毒学失败后，用于指导二线抗HIV治疗中逆转录酶抑制剂选择的表型和基因型分析。
J Antimicrob Chemother. 2014 Jul;69(7):1938-44. doi: 10.1093/jac/dku052. Epub 2014 Mar 14.
9
The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance.抗病毒药物耐药性出现后开发新型HIV-1逆转录酶和整合酶抑制剂的必要性
Scientifica (Cairo). 2012;2012:238278. doi: 10.6064/2012/238278. Epub 2012 Dec 31.
10
The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.HIV-1 逆转录酶中的连接域突变 N348I 增强了对依曲韦林和利匹韦林的耐药性，但通过降低病毒复制能力限制了 E138K 耐药突变的出现。
J Virol. 2014 Feb;88(3):1536-47. doi: 10.1128/JVI.02904-13. Epub 2013 Nov 13.

本文引用的文献

1
The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.HIV-1 逆转录酶连接亚结构域的 N348I 突变降低了与奈韦拉平的结合。
J Biol Chem. 2010 Dec 3;285(49):38700-9. doi: 10.1074/jbc.M110.153783. Epub 2010 Sep 27.
2
N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.HIV-1 逆转录酶中的 N348I 可以抵抗奈韦拉平在正链起始过程中引起的 RNase H 切割偏向。
J Biol Chem. 2010 Aug 27;285(35):26966-26975. doi: 10.1074/jbc.M110.105775. Epub 2010 Jun 8.
3
A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.一种核苷类和非核苷类逆转录酶抑制剂双重耐药的新分子机制。
J Virol. 2010 May;84(10):5238-49. doi: 10.1128/JVI.01545-09. Epub 2010 Mar 10.
4
Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.流行病学和生物学证据表明，HIV-1 逆转录酶中连接域突变 N348I 对 M184V 具有补偿作用。
J Infect Dis. 2010 Apr 1;201(7):1054-62. doi: 10.1086/651168.
5
N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.HIV-1 逆转录酶中的 N348I 突变与其他耐药突变联合降低了对替诺福韦和依曲韦林的敏感性。
AIDS. 2010 Jan 16;24(2):317-9. doi: 10.1097/QAD.0b013e3283315697.
6
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.抗艾滋病毒初治患者中感染非 B 型 HIV-1 亚型对依曲韦林（TMC-125）的耐药相关突变。
Antimicrob Agents Chemother. 2010 Feb;54(2):728-33. doi: 10.1128/AAC.01335-09. Epub 2009 Dec 14.
7
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.与依非韦伦治疗经非核苷类逆转录酶抑制剂治疗的 HIV-1 感染患者的病毒学应答相关的因素。
Antimicrob Agents Chemother. 2010 Jan;54(1):72-7. doi: 10.1128/AAC.01051-09. Epub 2009 Nov 9.
8
Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1.1型人类免疫缺陷病毒蛋白酶抑制剂耐药株中与适应性和药物敏感性相关的Gag决定簇
J Virol. 2009 Sep;83(18):9094-101. doi: 10.1128/JVI.02356-08. Epub 2009 Jul 8.
9
Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples.临床样本中与依曲韦林表型敏感性降低相关的额外HIV-1突变模式。
AIDS. 2009 Jul 31;23(12):1602-5. doi: 10.1097/QAD.0b013e32832d8771.
10
Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility.HIV-1逆转录酶连接域和核糖核酸酶H结构域突变对药物敏感性的影响。
AIDS Rev. 2008 Oct-Dec;10(4):224-35.